PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) has announced the appointment of Edward James Henderson as the public officer and director of its PreveCeutical (Australia) Pty Ltd. subsidiary with immediate effect.
The group noted that Henderson is HLB Mann Judd's managing partner, Business Advisory Services, Tax Consulting, Brisbane, Queensland, Australia.
It added that he is a respected business strategist with an extensive range of expertise and knowledge across a multitude of industries.
READ: PreveCeutical says current stage of analgesic research program soon to complete
In a statement, Stephen Van Deventer, PreveCeutical's chief executive officer, commented: "We are very pleased and fortunate to have James join our Board of Directors and take the role of Public Officer with our Subsidiary.
“Having a board member and Public Officer of his calibre and Australian expertise will be very valuable to the Company, especially at this time when we are transitioning from research to development and commercialization."
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
The company's current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
Contact the author at [email protected]
